show episodes
 
Loading …
show series
 
We are back for another High-Rise episode and this week we welcome a new special guest host Matt Hawkins, managing partner at Entourage Effect Capital. Matt brings some great perspective to the conversation as we delve into some of the latest developments on the Cannabis Administration and Opportunity Act. It is still to early to pass this importan…
 
Recently, The ASCO Post published an article titled ‘Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar'. On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been turned into a chronic disease for many people. He also d…
 
This week on the High-Rise Cy and Emily get right into the brass tax of recent market news and projections both in the U.S. and Canada. They also cover the latest update on banking for the cannabis industry and why Senator Cory Booker is walking back his stance a bit on this issue. Cowen Group a financial services and investment banking firm just a…
 
On this episode, we’re reviewing recommendations from the International Association for the Study of Lung Cancer on the use of liquid biopsy for lung cancer. We’ll also hear about a study that compared two regimens added to radiotherapy for pancreatic cancer. Coverage of stories discussed this week on ascopost.com: Consensus Statement From IASLC on…
 
This week, we’re reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we’ll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant cancers. Coverage of stories discussed this week on ascopost.com: FDA Gr…
 
This week, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with breast cancer may lead to increases in survival. Coverage of stories…
 
On this week’s High-Rise Cy and Emily discuss the termination of the $50M strategic investment between The Parent Company and Glass House, and some of the complex details around that decision. Jeffires Group investment banking firm and one of their top analysts Owen Bennett, released a 200 page report covering U.S. MSOs and what things can start lo…
 
Welcome back to another week of the High-Rise Podcast! In this episode Cy and Emily are joined by Jeremy Berke, senior reporter at Insider. Jermey recently published a report which examines "The Cost of Inequity" in the cannabis industry. The High-Rise crew delves into some of the details from this report and digs a little deeper. In other news, ou…
 
In this latest episode of the High-Rise we are excited to have with us Todd Harrison as a special guest host. Todd hails from a diverse background in finance, risk management, and investing that spans over three decades. He is the founding partner and CIO for CB1Capital as well as author of the book, “The Other Side of Wall Street” and is also the …
 
We are back for another news packed episode of the High-Rise with Cy and Emily. Big headlines in the MSO world as Columbia Care acquires CO heritage retail chain Medicine Man. Texas incrementally upgrades their MMJ program by a half a percentage — literally. The state of California makes a $100M investment in their cannabis industry, even though th…
 
This week, we’re continuing our coverage of Plenary Presentations from the 2021 ASCO Annual Meeting, including research on adjuvant pembrolizumab for patients with renal cell carcinoma; novel treatment options for advanced esophageal squamous cell carcinoma; and adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women wit…
 
Here we are again for another week of our laid back data backed conversation on all things cannabis. In this episode we are joined by the one and only Alan Brochstein of New Cannabis Ventures and 420investor. Our discussion leads us to Illinois and Michigan where we get into the some of the constrains and dysfunctions these 2 US states are facing i…
 
This week marks our 100th episode of the podcast! We launched at the start of the 2019 ASCO Annual Meeting, and this week, we’re reporting major findings from the 2021 Annual Meeting, including adjuvant therapy for patients with BRCA-mutated breast cancer, LuPSMA for metastatic prostate cancer, and an update on CodeBreak100, the trial that led to t…
 
Amazon makes an announcement that has the industry talking. We dive straight into what it all could mean with a special guest journalist from Forbes Will Yakowicz and how this might effect legalization and the industry going forward. The MORE Act has returned to Congress and we discuss the huge potential benefits if this gets passed into law soon, …
 
This week, we’re discussing the recent U.S. Preventive Services Task Force, or USPSTF, recommendation on colorectal cancer screening beginning at 45. Then, we’ll hear about a doublet regimen that produced durable responses in patients with advanced head and neck cancer. Lastly, we’ll hear about a study being presented during the ASCO Annual Meeting…
 
This week we get into the weeds with AYR and Cresco to see how their earnings might pan out. We talk about Gen Z share of wallet in an adult use world, plus a Sunnyside retail X YouGov study that shows 25% of Americans now consume cannabis. Lastly we get into a side effect of high tax rates known as 'looping'. As always there's never a dull moment …
 
The 2021 ASCO Annual Meeting kicked off this week with a premeeting presscast, where data from five studies to be presented at the conference were discussed . On this podcast, we’ll hear from two authors featured in that presscast about findings in non–small cell lung cancer and the effect of Medicaid expansion on long-term survival for patients wi…
 
In this episode we talk a bit about some recent US cannabis legalization news as it relates to members of the Republican party and about Chuck Schumer. We also talk about GTI with their G.A.R.P. and their earnings call, where GTI utilizes some groovy/dubby jams via Spotify. We get into Curaleaf and their potential investment moves into interstate c…
 
We’ll start off hearing about an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we’ll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic. Coverage of stories discussed this week on ascopost.c…
 
In this episode we are joined by Emily Paxhia of Poseidon Asset Management and Matt Karnes of GreenWave Advisors where we talk about the Sundial Growers acquisition of Inner Spirit Holdings, the latest news with OrganiGram's CEO, banking rates potentially lowering as a trend as seen with GTI, and 'Tilapia' High-Rise Cannabis MSOs, Products & Market…
 
This week, The ASCO Post sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor. The Marshalls are the coauthors of a new book entitled Off Our Chests: A Candid Tour Through the World of Cancer, publ…
 
In this episode we are joined by Emily Paxhia of Poseidon Asset Management and Matt Karnes of GreenWave Advisors where we talk about Canada's upcoming CBD strategy and MSO expansion. High-Rise Cannabis MSOs, Products & Market Analysis is a laid-back, data-backed discussion on the cannabis market with notable industry leaders.…
 
This week, we’ll discuss the findings of a trial that examined the efficacy of intensified therapy for patients with newly diagnosed locally advanced rectal cancer. Then, we’ll talk about the FDA’s approval of a new agent for advanced endometrial cancer. Coverage of stories discussed this week on ascopost.com: Addition of Neoadjuvant FOLFIRINOX to …
 
This week, we review data on the short-term safety of the COVID-19 vaccine in patients with cancer receiving immunotherapy. We’ll also discuss a study of the monoclonal antibody tislelizumab plus chemotherapy as first-line treatment for patients with advanced squamous non–small cell lung cancer. Coverage of stories discussed this week on ascopost.c…
 
On this week’s podcast, we’re continuing our coverage of the 2021 AACR Annual Meeting. We’ll hear from researchers on the role of cancer biology in treatment paradigms; novel strategies in the care of patients with brain metastases; and the influence of diet on cancer development and response to therapy. To listen to more podcasts from ASCO, visit …
 
The 2021 AACR Annual Meeting launched week 1 of a two-week program on April 10 featuring plenary sessions and major scientific symposia. Week 2 will take place in May. In this week’s podcast, The ASCO Post speaks with faculty at AACR’s annual meeting who presented clinical research in non–small cell lung cancer, non-Hodgkin lymphoma, and uveal mela…
 
This week, we’ll be discussing a recent presentation that parsed out differences in disease seen in younger vs older women with breast cancer. We’ll also hear about an update to the NCCN Guidelines for triple-negative breast cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts.
 
This week, we’re again discussing findings presented during the Society of Gynecologic Oncology’s (SGO) Virtual 2021 Annual Meeting on Women’s Cancer. We’re hearing from three presenting authors on a number of topics, including maintenance olaparib for newly diagnosed advanced ovarian cancer; maintenance niraparib for platinum-sensitive ovarian can…
 
The Society of Gynecologic Oncology’s virtual 2021 Annual Meeting on Women’s Cancer is taking place from March 19 to 25. This week, we’re hearing about findings presented at the meeting in endometrial and ovarian cancers. To listen to more podcasts from ASCO, visit asco.org/podcasts.
 
More than a year into the COVID-19 pandemic, researchers are beginning to examine the effects of the virus in the larger health-care sphere. This week, we’ll review a report on an observed increase of breast cancer diagnoses in Italy after pandemic-related screening interruptions. We’ll also discuss two FDA approvals that occurred over the past wee…
 
This week, we’re discussing recent regulatory decisions, ranging from FDA approvals in multiple myeloma and non–small cell lung cancer to the withdrawal of a widely used drug’s indication for small cell lung cancer. Coverage of stories discussed this week on ascopost.com: FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refr…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login